BioCentury
ARTICLE | Clinical News

Exelon Patch rivastigmine regulatory update

May 6, 2013 7:00 AM UTC

Novartis disclosed in its 1Q13 earnings that EMA approved an expansion of the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to moderately sever...